| 中文名 | N-BOC-3-甲磺酰氧基哌啶 |
|---|---|
| 英文名 | N-Boc-3-mesyloxypiperidine |
| 中文别名 |
N-BOC-3-甲磺酰氧基哌啶N-BOC-3-甲磺酰氧基哌啶
3-((甲磺酰基)氧基)哌啶-1-甲酸叔丁酯 3-(甲基磺酰基氧基)哌啶-1-羧酸叔丁酯 1-BOC-3-[(甲磺酰基)氧基]哌啶 N-BOC-3-OMS-哌啶 N-Boc-3-甲基磺酰氧基哌啶 |
| 英文别名 |
tert-Butyl 3-[(methylsulfonyloxy)]-1-piperidinecboxylate
tert-Butyl 3-((methylsulfonyl) 2-Methyl-2-propanyl 3-[(methylsulfonyl)oxy]-1-piperidinecarboxylate tert-Butyl 3-Methylsulfonyloxypiperidine-1-carboxylate tert-Butyl 3-(methanesulfonyloxy)piperidine-1-cboxylate 1-Boc-3-methanesulphonyloxypiperidine tert-Butyl 3-Methylsulfonyloxypiperidine-1-cboxylate 3-((methylsulfonyl)oxy)piperidine-1-cboxylate tert-Butyl 3-[(methylsulfonyl)oxy]piperidine-1-carboxylate tert-Butyl 3-Methylsulfonyloxypiperidin-1-carboxylate N-BOC-3-(Methylsulfonyloxy)piperidine 1,1-Dimethylethyl 3-[(methylsulfonyl)oxy]-1-piperidinecboxylate 3-(Methylsulfonyloxy)piperidine-1-cboxylic acid tert-butyl ester tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate 1-Boc-3-methanesulfonyloxy-piper 1-Piperidinecboxylic acid, 3-[(Methylsulfonyl)oxy]-, 1,1-diMethylethyl ester 3-methylsulfonyloxy-1-piperidinecboxylic acid tert-butyl ester 3-methanesulfonyloxy-N-t-butoxycarbonylpiperidine 1-Piperidinecarboxylic acid, 3-[(methylsulfonyl)oxy]-, 1,1-dimethylethyl ester tert-Butyl 3-Methylsulfonyloxypiperidin-1-cboxylate tert-Butyl 3-[(methylsulfonyl)oxy]-1-piperidinecarboxylate 1-(tert-Butoxycbonyl)-3-(methanesulfonyloxy)piperidine 1-tert-butoxycarbonylpiperid-3-yl methanesulfonate |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 407.2±34.0 °C at 760 mmHg |
| 分子式 | C11H21NO5S |
| 分子量 | 279.353 |
| 闪点 | 200.1±25.7 °C |
| 精确质量 | 279.114044 |
| PSA | 81.29000 |
| LogP | 0.64 |
| 蒸汽压 | 0.0±0.9 mmHg at 25°C |
| 折射率 | 1.500 |
| 储存条件 | 室温,干燥 |
| 海关编码 | 2933399090 |
|---|
|
~99%
129888-60-4 |
| 文献:VERTEX PHARMACEUTICALS INCORPORATED; Charrier, Jean-Damien; Durrant, Steven John; Knegtel, Ronald Patent: US2013/115310 A1, 2013 ; Location in patent: Paragraph 0248; 0249 ; |
|
~90%
129888-60-4 |
| 文献:BIOGEN IDEC MA INC.; SUNESIS PHARMACEUTICALS, INC.; HOPKINS, Brian, T.; SCOTT, Daniel; CONLON, Patrick; JENKINS, Tracy, J.; POWELL, Noel; GUAN, Bing; CURERVO, Julio, H.; WANG, Deping; TAVERAS, Art Patent: WO2012/58645 A1, 2012 ; Location in patent: Page/Page column 210 ; WO 2012/058645 A1 |
|
~94%
129888-60-4 |
| 文献:The United States of America as represented by the Department of Health and Human Services Patent: US5571832 A1, 1996 ; US 5571832 A |
|
~%
129888-60-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 35, # 23 p. 4334 - 4343 |
|
~%
129888-60-4 |
| 文献:Journal of Medicinal Chemistry, , vol. 35, # 23 p. 4334 - 4343 |
| 上游产品 6 | |
|---|---|
| 下游产品 5 | |
| 海关编码 | 2933399090 |
|---|---|
| 中文概述 | 2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |